RADically Disrupt Cancer

Gilead Raday (MSc., M.Phil), Co-Founder & CEO 

Biopharma executive with a track record in developing new drugs all the way to FDA approval and commercialization. An insightful and experienced integrator of scientific innovation, R&D operations, clinical & regulatory strategy, with commercial, financial and corporate development.

Prof. Varda Shoshan-Barmatz(Ph.D), Co-Founder, Inventor and Lead Scientist

Professor at the Department of Life-Sciences at Ben-Gurion University (BGU) in Israel and a renowned scientist and leading expert in the field of mitochondrial biology and cancer research. Prof. Shoshan-Barmatz has held various leadership positions, including as Director of Israel’s National Institute of Biotechnology in the Negev (NIBN) and is a prolific researcher and innovator.

Prof. Dario C. Altieri (MD), Scientific Advisor – President and CEO of The Wistar Institute, Philadelphia, USA, the 1st NCI-designated Basic Cancer Center and a global leader in biomedical research. Prof. Altieri is a distinguished cancer researcher credited for the discovery and characterization of Survivin as a key oncoprotein, and clinical validation of Survivin as a therapeutic target and predictive/prognostic disease biomarker.

Prof. Nir Peled (MD, Ph.D), Medical Advisor

Head of the Oncology Division at Shaare-Zedek Medical Center at the Hebrew University, Jerusalem, Israel. A KOL in the field of thoracic oncology, including personalized targeted therapy, immunotherapy, cancer evolution, biomarker development, and early detection. Prof. Peled was a board member at the International Association of Lung Cancer (IASLC) and the past-chair of its Screening & Early Detection committee, as well as the previous Chair of the Thoracic Cancer Assembly of the European Thoracic Society.  Currently he is the head of the Global Multidisciplinary Practice Standards of the IASLC.

1. Manikandan Santhanam, Venkatadri Babu, Anna Shteinfer-Kuzmine, Swaroop Kumar Pandey, Larisa Gheber, Ph.D, Gilead Raday, Varda Shoshan-Barmatz. Survivin/BIRC5-derived peptide disrupts survivin dimerization and cell division and induces multifaceted anti-cancer effects, Molecular Therapy: Oncology Vol. 34 March 2026

2. Santhanam M, Kumar Pandey S, Shteinfer-Kuzmine A, Paul A, Abusiam N, Zalk R, Shoshan-Barmatz V. Interaction of SMAC with a survivin-derived peptide alters essential cancer hallmarks: Tumor growth, inflammation, and immunosuppression. Mol Ther. 2024 Jun 5;32(6):1934-1955. doi: 10.1016/j.ymthe.2024.04.007. Epub 2024 Apr 5. PMID: 38582961; PMCID: PMC11184343.

3. Sally P. Wheatley, Dario C. Altieri, Survivin as a glance, J Cell Sci (2019) 132 (7): jcs223826. 

4. Wang, Q.; Greene, M.I., Survivin as a Therapeutic Target for the Treatment of Human Cancer. Cancers (2024), 16, 1705. https://doi.org/10.3390/cancers16091705 

SURVIVIN is a validated ‘holy-grail’ ‘undruggable’ pan-cancer target & biomarker, which is constitutively overexpressed in 60-90% of cancer patients. SURVIVIN drives tumor proliferation and evasion of apoptosis and is associated with poor prognosis and increased tumor resistance to chemotherapy & radiation. Normally expressed only transiently, during mitosis, SURVIVIN is absent in most differentiated normal cells, making it an ideal selective cancer target.

Over 240,000 new lung cancer patients in the US every year 

5-year survival of lung cancer patients is still unacceptably low at app. 27%

Approximately 67,000 of these new lung cancer patients suffer from NSCLC Adenocarcinoma with elevated expression of SURVIVIN.

These 67,000 patients each year could RADically benefit from our targeted therapy  

https://seer.cancer.gov/statfacts/html/lungb.html?utm_source=chatgpt.com

We identified the SURVIVIN-derived peptide segment which is key to its dimerization, and essential for its activity via protein protein interactions (PPIs). We engineered a cell penetrating nucleus-directed "decoy peptide" optimized for plasma stability to directly and selectivity inhibit SURVIVIN and its PPIs.

Administering our drug in-vivo in CDX cancer model resulted in profound effects: Over 90% Tumor Growth Inhibition without toxicity (sustained cytostasis). Unprecedented results for SURVIVIN targeting, outperforming Paclitaxel & Docetaxel in the same model. 

RADpep-001 demonstrates pan-cancer potential with potent & selective killing of multiple cancer cell types, including Non-Small Cell Lung Cancer, Pancreatic Cancer, Neuroblastoma, Glioblastoma & Prostate Cancer.

Our approach leverages use of SURVIIVIN expression as a biomarker to direct our treatment to the patients who are most likely to benefit.

•Highly selective modality with pan-cancer potential and no observed toxicity nor anticipated off target effects

Highly promising as anti-cancer monotherapy against multiple solid and hematological cancers in patients that are that overexpress SURVIVIN (SURVIVIN-positive biomarker)

Potential for synergy in combination with Immune-therapy and with chemo/radiation therapy

Highly selective with no notable toxicity

State-of-the-art synthetic manufacturing assures cost-effective manufacturing of high and consistent product quality